Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Status:
Withdrawn
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
Primary Objective:
To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC)
on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to
Alzheimer's disease (AD).
Secondary Objective:
- To evaluate safety and tolerability of Leukine versus placebo.
- To explore the effect of Leukine versus placebo on cognitive performance.
- To collect biospecimens for future biomarker research.